Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00410761 · OUTCOME

Duration of Response (DoR)

An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer · Source last updated 2025-09-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
Months
Interval / dispersion
95% Confidence Interval
Time frame
RECIST tumour assessments were performed at screening (within 3 weeks before date of randomisation), then once every 12 weeks up to and including discontinuation of blinded study treatment, unless patients had withdrawn consent

What was measured

Response is defined as a confirmed best objective response of CR or PR. Duration of response is defined as time from the date of first documented response until date of documented progression or death in the absence of disease progression (provided death is within 3 months of last RECIST assessment). Values are estimated as the medians weren't met

Analysis population: DoR is a time to event endpoint and because the medians were not met in this study there is no appropriate measure of dispersion of the median

Groups in this outcome

Vandetanib 300 mg

Vandetanib (300 mg daily)

Placebo

Placebo daily

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Vandetanib 300 mg104
Placebo13

Reported measurements

Source class 1
Values in Months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Vandetanib 300 mg22.2Not reportedNANADoR is a time to event endpoint and because the medians were not met in this study there is no appropriate measure of dispersion of the median
Placebo16.3Not reportedNANADoR is a time to event endpoint and because the medians were not met in this study there is no appropriate measure of dispersion of the median
Complete source fields
classes
  1. categories
    1. measurements
      1. comment
        DoR is a time to event endpoint and because the medians were not met in this study there is no appropriate measure of dispersion of the median
        group Id
        OG000
        lower Limit
        NA
        upper Limit
        NA
        value
        22.2
      2. comment
        DoR is a time to event endpoint and because the medians were not met in this study there is no appropriate measure of dispersion of the median
        group Id
        OG001
        lower Limit
        NA
        upper Limit
        NA
        value
        16.3
denoms
  1. counts
    1. group Id
      OG000
      value
      104
    2. group Id
      OG001
      value
      13
    units
    Participants
description
Response is defined as a confirmed best objective response of CR or PR. Duration of response is defined as time from the date of first documented response until date of documented progression or death in the absence of disease progression (provided death is within 3 months of last RECIST assessment). Values are estimated as the medians weren't met
dispersion Type
95% Confidence Interval
groups
  1. description
    Vandetanib (300 mg daily)
    id
    OG000
    title
    Vandetanib 300 mg
  2. description
    Placebo daily
    id
    OG001
    title
    Placebo
param Type
MEDIAN
population Description
DoR is a time to event endpoint and because the medians were not met in this study there is no appropriate measure of dispersion of the median
reporting Status
POSTED
time Frame
RECIST tumour assessments were performed at screening (within 3 weeks before date of randomisation), then once every 12 weeks up to and including discontinuation of blinded study treatment, unless patients had withdrawn consent
title
Duration of Response (DoR)
type
SECONDARY
unit Of Measure
Months

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice